Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments (fo
Companies such as Google parent Alphabet, BlackRock and Brookfield Asset Management are set to be in attendance.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...